tbuckley/cabot-search huggingface dataset:
Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?
Authors: Manuel Noben, Bram Verstockt, Magali de Bruyn, Nikolai Hendriks, Gert Van Assche, Séverine Vermeire, Catherine Verfaillie, Marc Ferrante
Journal: Gut (2017)

With great interest we read the paper by Dotti et al ,1 who identified a set of differentially expressed genes in epithelial organoid cultures (EpOCs) derived from patients with UC compared with EpOCs from healthy controls.

Similarly, we created an EpOC library from patients with UC (n=17), Crohn's disease (CD, n=12) and healthy controls (n=10). First, we assessed the potential of isolated intestinal crypts to grow into organoids (colony forming units). We observed that a similar percentage of organoids was formed from intestinal crypts isolated from controls and patients with UC or CD. Moreover, intestinal crypts isolated from macroscopically inflamed and non-inflamed tissue had similar potential to form organoids (figure 1A). Although we used a slightly divergent differentiation medium,2 the expansion and differentiation capacity of our organoids was similar as demonstrated by Dotti et al .



Figure 1 
(A) Colony forming units (CFUs) determined by quantification of the number of seeded crypts at the day of isolation and organoid formation after 7 days. CFUs are expressed as a percentage of organoids representative to the original number of seeded crypts. (B) Relative mRNA expression levels of leucine-rich repeat-containing G-protein coupled receptor 5 ( LGR5 ), mucin2 ( MUC2 ) and protein atonal homologue 1 ( ATOH1 ). mRNA levels were …
Intensified 1st Cycle Rituximab (R) Plus 8th Cycles of R-CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) Chemotherapy In Patients with Advanced or Bulky CD20+ Diffuse Large B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis.
Authors: Jin Seok Kim, Won Seog Kim, Seok Jin Kim, Hyeon Seok Eom, Deok-Hwan Yang, Yang Soo Kim, Hyo Jung Kim, Min Kyoung Kim, Suk-Joong Oh, Sung-Soo Yoon, Hun-Mo Ryoo, Jae-Yong Kwak, Jae Hoon Lee, Chul Won Choi, Hye Jin Kang, Yeung-Chul Mun, yun Deok Kim, Cheolwon Suh
Journal: Blood (2010)
Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial
Authors: Morten Ruhwald, Henrik Aggerbeck, Rafael Vázquez Gallardo, Søren T Hoff, José I Villate, Bettine Borregaard, José A Martinez, Ingrid Kromann, Antón Penas, Luis L Anibarro, Maria Luiza de Souza-Galvão, Francisca Sánchez, Jose Ángel Rodrigo-Pendás, Antoni Noguera-Julian, Xavier Martínez-Lacasa, Maria Victoria Tuñez, Virginia Leiro Fernández, Joan P Millet, Antonio Moreno, Nazaret Cobos, José M Miró, Llanos Roldan, Angels Orcau, Peter Andersen, Joan A Caylá
Journal: The Lancet Respiratory Medicine (2017)
Chimeric Leukemic Protein PLZF/RARα Functions as an Adoptor for Cul3-Based E3 Ubiquitin Ligase To Regulate Proteosomal Degradation of RXRα.
Authors: Masahiro Onozawa, Takeshi Kondo, Hiroe Kanamori, Kaoru Kahata, Satoshi Hashino, Masahiro Asaka
Journal: Blood (2006)
ATPS-84HYDROXYUREA SENSITIZES PATIENT-DERIVED GLIOBLASTOMA TUMORS TO TEMOZOLOMIDE IRRESPECTIVE OF MGMT STATUS
Authors: Jian Teng, Seyedali Hejazi, Lotte Hiddingh, Hiroaki Wakimoto, Mark de Gooijer, Marco Barazas, Andrew Chi, Pieter Wesseling, Thomas Wurdinger, Tracy Batchelor, Bakhos Tannous
Journal: Neuro-Oncology (2015)

Glioblastoma (GBM) is the most common and most aggressive primary malignant brain tumor. Standard-of-care treatment involves radiation, chemotherapy (temozolomide; TMZ), and maximal surgical resection of the tumor. The 5-year survival rate of patients with GBM is <10%, a colossal failure that has been partially attributed to intrinsic and/or acquired resistance to TMZ through MGMT tumor status. Through drug screening, we identified hydroxyurea (HU), an FDA-approved drug, to sensitize GBM cells to TMZ. HU synergized with TMZ in both newly diagnosed GBM with different MGMT status as well as recurrent, TMZ-resistant, tumors in culture as well as in different quantitative intracranial in vivo models. HU acts specifically on the S-phase of the cell cycle by inhibiting the enzyme ribonucleotide reductase M2. Knockdown of this enzyme using RNA interference and other known inhibitors exerted a similar effect to HU in combination with TMZ both in vitro and in vivo. Although HU has been previously evaluated in malignant gliomas in combination with radiation or cytotoxic chemotherapy, and has shown limited efficacy, it was never evaluated in combination with TMZ. In summary, we demonstrate preclinical efficacy of ribonucleotide reductase inhibition using hydroxyurea in combination with TMZ for the treatment of glioblastoma, which warrant further evaluation in a clinical setting.
VIDAS D-Dimer in Combination with Clinical Pre-Test Probability to Rule out Pulmonary Embolism. A Systematic Review of the Management Outcome Studies.
Authors: Marc Carrier, Marc Righini, Reza Karami Djurabi, Menno Huisman, Arnaud Perrier, Philip Wells, Walter Wuillemin, Gregoire Le Gal
Journal: Blood (2008)
Combined Analysis Using Visual and SUV-Based Quantitative Assessments Improves Predictive Value of Interim Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated with R-CHOP
Authors: Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, So Yeon Jeon, Chang-Yeol Yim, Yeon-Hee Han, Myung-Hee Sohn, Bohee Lee, Jeong-A Kim, Young Ha Park, Woo Hee Choi, Hee Sun Kim, Jae-Yong Kwak
Journal: Blood (2012)
Abstract 17428: Discharge Prescriptions for Spironolactone and 30-day All-cause Readmission in Hospitalized Medicare Beneficiaries With Heart Failure, LVEF Less Than 45% and eGFR Less Than 45
Authors: Chakradhari Inampudi, Sridivya Parvataneni, Prakash Deedwania, Gregg C Fonarow, Sumanth D Prabhu, Javed Butler, Charity J Morgan, Wilbert S Aronow, Paul W Sanders, Richard M Allman, Ali Ahmed
Journal: Circulation (2013)
The Ex-Vivo Expansion of Cytokine Induced Killer (CIK) Cells Can Be Optimized Predicting Cell Expansion Dynamics by Means of Multivariate Statistical Data Analysis
Authors: Francesco Rodeghiero, Cristina Zanon, Matteo Stocchero, Elena Albiero, Silvia Castegnaro, Katia Chieregato, Domenico Madeo, Giuseppe Astori
Journal: Blood (2012)
ADAMTS13 Regulates Neutrophil Recruitment in a Mouse Model of Invasive Pulmonary Aspergillosis
Authors: Markus Radsak, Steve Prüfer, Katharina Ebner, Michael Weber, Sebastian Reuter, Pamela Stein, Inge Scharrer, Michael Stassen, Hansjörg Schild, Kerstin Jurk, Markus Bosmann
Journal: Blood (2014)
Erythropoietin Production in Vivo after a Fourteen Days Exposition to Hyperbarism
Authors: Bianca Maria Ricerca, Salvatore Vagnoni, Anna Maria D’Amore, Enrico Di Stasio, Celestino Pio Lombardi, Gabriele Storti, Rodolfo Proietti, Sergio Storti, Luca Revelli
Journal: Blood (2008)
Genetic typing of bronchial asthma afflicted people according to polymorphous genes for the purpose of disease progress risk factors detection
Authors: Natalia Dudareva
Journal: European Respiratory Journal (2011)

The article presents the data concerning frequency allocation.of gaplotypes and alleles of genes belonging to family glutathione-S-transferase (GSTM and GSTT), genes of cytokines (IL-6 and TNF-A), cytotoxic receptor of T-lymphocyte gene (CTLA-4) and gene of vitamin D receptor in case of afflicted people with uncontrolled bronchial asthma clinical course. The data are compared to the frequency allocation of gaplotypes and alleles of the foregoing genes in the citizens' population in different areas of Belarus. The received data concerning the frequency allocation of gaplotypes and alleles of genes CTLA-4, TNF-A, GSTM and GSTT didn't authentically differ from the frequency of Belarusian population. No authentic frequency allocation differences were detected. However there were authentically proved differences in frequency allocation of gaplotypes and alleles of genes between four polymorphous locuses of VDR-gene in case of bronchial asthma afflicted people from the one detected in the population. The VDR gene's frequency of homozygotes FF at FokI locus (36,0%) is higher than the population's one (29,1%). The VRD gaplotype TtAaBbFF appeared to be the bronchial asthma afflicted people's most spread one (17,4%) (in Belarusians' population selection the most spread gaplotype is TtAaBbFf). The received data indicate the connection of VDR- polymorphism with uncontrolled bronchial asthma and the utility of conducting the further research concerning the influence of vitamin D on treatment.
Oral RevlimidR Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.
Authors: Antonio Palumbo, Patrizia Falco, Pellegrino Musto, Paolo Corradini, Francesco Di Raimondo, Giuseppe Rossi, Nicola Giuliani, Fortunato Morabito, Annalisa Luraschi, Antonietta Falcone, Paola Omedè, Francesca Gay, Ilaria Avonto, Maria Teresa Ambrosini, Sara Bringhen, Jerome Zeldis, Robert Knight, Mario Boccadoro, Maria Teresa Petrucci
Journal: Blood (2005)
Genomic Loss of the Mismatched HLA Locus in Leukemia Is a Major Mechanism of in Vivo Escape from T Cell Immunosurveillance Following Haploidentical HSCT
Authors: Luca Vago, Serena Kimi Perna, Monica Zanussi, Benedetta Mazzi, Maria Teresa Lupo Stanghellini, Nicola Flavio Perrelli, Barbara Forno, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Maurizio Ferrari, Silvano Rossini, Maria Grazia Roncarolo, Claudio Bordignon, Chiara Bonini, Fabio Ciceri, Katharina Fleischhauer
Journal: Blood (2008)
A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay.
Authors: Daniel A Pollyea, Sonali Smith, Nathan Fowler, Thomas E Boyd, Ashley M Smith, Mint Sirisawad, Lee A Honigberg, Ahmed Hamdy, Ranjana Advani
Journal: Blood (2009)
Phase I Trial of Fenretinide (4-HPR) Intravenous Emulsion for Hematologic Malignancies.
Authors: Ann Mohrbacher, Martin Gutierrez, Anthony J. Murgo, Shivaani Kummar, C. Patrick Reynolds, Barry J. Maurer, Susan Groshen, Lori Vergara, Min H. Kang, Allen S. Yang
Journal: Blood (2007)
The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB
Authors: Jose Manuel Garcia-Heredia, Antonio Lucena-Cacace, Eva M. Verdugo-Sivianes, Marco Pérez, Amancio Carnero
Journal: Clinical Cancer Research (2017)

Purpose: Cancer stem cells (CSC) are self-renewing tumor cells, with the ability to generate diverse differentiated tumor cell subpopulations. They differ from normal stem cells in the deregulation of the mechanisms that normally control stem cell physiology. CSCs are the origin of metastasis and highly resistant to therapy. Therefore, the understanding of the CSC origin and deregulated pathways is important for tumor control.Experimental Design: We have included experiments in vitro, in cell lines and tumors of different origins. We have used patient-derived xenografts (PDX) and public transcriptomic databases of human tumors.Results: MAP17 (PDZKIP1), a small cargo protein overexpressed in tumors, interacts with NUMB through the PDZ-binding domain activating the Notch pathway, leading to an increase in stem cell factors and cancer-initiating-like cells. Identical behavior was mimicked by inhibiting NUMB. Conversely, MAP17 downregulation in a tumor cell line constitutively expressing this gene led to Notch pathway inactivation and a marked reduction of stemness. In PDX models, MAP17 levels directly correlated with tumorsphere formation capability. Finally, in human colon, breast, or lung there is a strong correlation of MAP17 expression with a signature of Notch and stem cell genes.Conclusions: MAP17 overexpression activates Notch pathway by sequestering NUMB. High levels of MAP17 correlated with tumorsphere formation and Notch and Stem gene transcription. Its direct modification causes direct alteration of tumorsphere number and Notch and Stem pathway transcription. This defines a new mechanism of Notch pathway activation and Stem cell pool increase that may be active in a large percentage of tumors. Clin Cancer Res; 23(14); 3871-83. ©2017 AACR.
The chromatin remodeling factor CHD7 controls cerebellar development by regulating reelin expression
Authors: Danielle E. Whittaker, Kimberley L.H. Riegman, Sahrunizam Kasah, Conor Mohan, Tian Yu, Blanca Pijuan Sala, Husam Hebaishi, Angela Caruso, Ana Claudia Marques, Caterina Michetti, María Eugenia Sanz Smachetti, Apar Shah, Mara Sabbioni, Omer Kulhanci, Wee-Wei Tee, Danny Reinberg, Maria Luisa Scattoni, Holger Volk, Imelda McGonnell, Fiona C. Wardle, Cathy Fernandes, M. Albert Basson
Journal: Journal of Clinical Investigation (2017)

The mechanisms underlying the neurodevelopmental deficits associated with CHARGE syndrome, which include cerebellar hypoplasia, developmental delay, coordination problems, and autistic features, have not been identified. CHARGE syndrome has been associated with mutations in the gene encoding the ATP-dependent chromatin remodeler CHD7. CHD7 is expressed in neural stem and progenitor cells, but its role in neurogenesis during brain development remains unknown. Here we have shown that deletion of Chd7 from cerebellar granule cell progenitors (GCps) results in reduced GCp proliferation, cerebellar hypoplasia, developmental delay, and motor deficits in mice. Genome-wide expression profiling revealed downregulated expression of the gene encoding the glycoprotein reelin (Reln) in Chd7-deficient GCps. Recessive RELN mutations have been associated with severe cerebellar hypoplasia in humans. We found molecular and genetic evidence that reductions in Reln expression contribute to GCp proliferative defects and cerebellar hypoplasia in GCp-specific Chd7 mouse mutants. Finally, we showed that CHD7 is necessary for maintaining an open, accessible chromatin state at the Reln locus. Taken together, this study shows that Reln gene expression is regulated by chromatin remodeling, identifies CHD7 as a previously unrecognized upstream regulator of Reln, and provides direct in vivo evidence that a mammalian CHD protein can control brain development by modulating chromatin accessibility in neuronal progenitors.
Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.
Authors: Martin H. Dreyling, Roswitha Forstpointner, Hans-Peter Boeck, Roland Repp, Hannes Wandt, Christiane Pott, John Francis Seymour, Bernd Metzner, Annette Haenel, Tanja Lehmann, Frank Hartmann, Hermann Einsele, Michael Unterhalt, Wolfgang Hiddemann
Journal: Blood (2006)
ATCT-19SIGNIFICANCE OF TEMOZOLOMIDE RE-CHALLENGE AFTER PROGRESSION OF MALIGNANT GLIOMAS IN MAINTAINING PERFORMANCE STATUS OF THE PATIENTS – MULTICENTER COOPERATIVE STUDY
Authors: Shohei Kohno, Takanori Ohnishi, Tomotsugu Ichikawa, Isao Date, Keisuke Miyake, Takeshi Tamiya, Teruyoshi Kgeji, Shinji Nagahiro, Makoto Ideguchi, Michiyasu Suzuki, Kanbe Atsushi, Takashi Watanabe, Kenshi Miyazaki, Yasuhiko Akiyama, Nobuhisa Matsushita, Masaaki Uno
Journal: Neuro-Oncology (2015)

BACKGROUND: Recent standard therapy for newly-diagnosed malignant gliomas consists of tumor resection, followed by chemotherapy with temozolomide (TMZ) concomitant with radiotherapy, and maintenance chemotherapy with TMZ. We found that continuous administration of TMZ did not deteriorate performance status (PS) of some patients who presented progressive disease (PD) during the maintenance therapy. In the present multicenter clinical study, we investigated whether continuous TMZ administration is effective for maintenance of PS compared to the therapy with other chemotherapeutic agents or no treatment in the patients showing PD in the maintenance chemotherapy with TMZ. METHODS: Patients diagnosed as grade 3 or 4 malignant gliomas who presented PD during the maintenance chemotherapy with TMZ were assigned to two groups; a continuous TMZ administration group (TMZ(+) ) or a group with other therapy (including no treatment) (TMZ(-) ) based on the will of patients. Between the two groups, KPS, median survival time from recurrence and adverse events were evaluated. The planned sample size was 39 (TMZ(+) group 26 patients, TMZ(-) group 13 patients). Registration period was 5.5 years and follow-up period was one year. (UMIN 000014688) RESULTS: Between 2009 and 2014, 43 patients have been registered. Suppression of PS deterioration in TMZ(+) group (30 patients) was maintained two or four months longer than that in TMZ(-) group (13 patients). Median survival time from recurrence in TMZ(+) group and TMZ(-) group were 14 and 9 months, respectively survival time of TMZ(+) group was significantly longer than that of TMZ(-) group (P < 0.05). There was no severe adverse events in TMZ(+) group. CONCLUSION: Re-challenge of TMZ in the patients with recurrent malignant glioma was effective for maintaining the PS for several months. Continuous TMZ treatment may be one of the treatment option at the time of relapse in keeping the QOL of patients.
A phase II trial of PTK787/ZK 222584 (PTK787) in recurrent high-grade meningioma.
Authors: S. A. Grimm, M. C. Chamberlain, J. Chandler, K. Muro, L. Rice, K. McCarthy, A. Rademaker, I. B. Helenowski, S. K. Johnston, M. M. Mrugala, J. J. Raizer
Journal: Journal of Clinical Oncology (2011)

2046 Background: Systemic treatment options are limited for patients with recurrent meningioma. VEGF and PDGF promote angiogenesis and cellular proliferation. PTK-787 is an oral inhibitor of VEGF and PDGF receptors. The primary endpoint was to determine overall response rate. Secondary endpoints were 6-month progression-free survival (PFS-6) and overall survival. Methods: Patients (pts) with histologically confirmed recurrent WHO Grade 2 or 3 meningioma were eligible. Pts had no limit on prior therapies though must have included surgery and radiotherapy, a KPS ≥60, and were not taking enzyme inducing anticonvulsants. PTK-787 administration began at 250 mg BID and increased by 250 mg/day weekly to a dose of 500 mg BID. Clinical examinations were performed after each 4-week cycle and imaging every 8 weeks. Responses were graded using modified Macdonald criteria. Results: 21 pts were treated: 14 grade 2 and 7 grade 3 meningiomas (11 men; 10 women). Median age was 59 (29-88) years. Median KPS was 80 (60-100). Median number of cycles was 2 (range < 1-14) with one patient remaining on treatment. Main toxicities were transaminase elevation grade 4 (n=1) and 3 (n=3), fatigue grade 3 (n=4) and rash grade 3 (n=2). 3 pts were withdrawn early due to toxicity and were not evaluable for response. Best response in the remaining 17 pts was PR (n=1; 5.8%), SD (n= 12; 70.6%) and PD (n = 5; 29.4%). Overall PFS-6 and 12 was 37.5% and 12.5%; median time to progression was 3.7 m grade 2 and 3.6 m grade 3 months among the 21 pts (intent to treat). Median overall survival was 22.9 m for grade 2 and 19.6 m for grade 3. Conclusions: The combination VEGF/PDGF inhibition in pts with recurrent or progressive high-grade meningiomas can lead to disease stabilization. Targeted therapy may have a better role than cytotoxic therapies given the limited activity of available agents and suggest further studies with VEGF signaling pathway inhibition are warranted.
Quantitate Detect of the Methylation of Three Hematopathy Patients’ P16 Gene
Authors: Bao-An Chen, Bei-ming Shou, Dong-rui Zhou, De-long Liu, Jia-hua Ding, Chong Gao, Yun-Yu Sun, Jun Wang, Jian Cheng, Gang Zhao, Hui-hui Song, Wen Bao, Jue-qiong Wang, Peng Yuan, Xiao-ping Pei, Ning-na Chen, Xu-dong Ma, Zu-hong Lu
Journal: Blood (2008)
High Incidence of Ancestral HLA Haplotype 8.1 and Incomplete DH-JH Immunoglobulin Rearrangement in Persistent Polyclonal B-Cell Lymphocytosis.
Authors: Dariusz Wolowiec, Miroslaw Majewski, Jacek Nowak, Beata Stella-Holowiecka, Angelika Krawcewicz, Renata Mika-Witkowska, Hanna Makuch-Lasica, Iwona Solarska, Olga Haus, Ewa Duszenko, Kazimierz Kuliczkowski, Krzysztof Warzocha
Journal: Blood (2005)
Impact of out-of-pocket expenses on cancer care.
Authors: Y. Zafar, A. M. Goetzinger, R. Fowler, A. Gblokpor, D. Warhadpande, D. H. Taylor, D. Schrag, J. M. Peppercorn, A. P. Abernethy
Journal: Journal of Clinical Oncology (2011)

6006 Background: How do out-of-pocket expenses for cancer care (OOPE) impact patient-reported lifestyle, quality, and satisfaction with cancer care? Methods: We recruited patients at Duke University Medical Center and from a national pool of applicants to the Healthwell Foundation (HF), a non-profit organization which assists the underinsured with healthcare costs. Eligible patients were receiving breast, lung, or colorectal cancer treatment. Eligibility was independent of receiving HF assistance. We did not share identified data with HF. Patients completed surveys on strategies to cope with OOPE, satisfaction with care, and 4 weekly expense diaries. Associations between demographics, coping strategies, and OOPE were examined. Results: 127 patients were enrolled (85% via HF), with a mean age of 65 years (range 41-88). Most were Caucasian (84%), female (94%), had breast cancer (84%), and had non-metastatic cancer (60%). All were insured; 64% had Medicare or Medicare plus supplemental insurance. 22% were employed, 51% were retired, and 73% had annual household income <$40,000. 45% perceived a significant or catastrophic financial burden with OOPE. OOPE averaged $1266/month. The largest proportion of OOPE was attributed to prescription medication ($523/month, 41%). Other monthly costs included: medical equipment ($197; 14%), travel ($122; 10%), special diet ($72; 6%), and non-prescription drugs ($68; 5%). As financial burden increased, patients used more strategies to cope with OOPE (p<0.001). To cope with OOPE, 52% spent less on food and clothing, 76% spent less on leisure activities like eating out or movies, 47% used all or part of their savings, 30% did not fill prescriptions, 20% took less medication than prescribed, and 49% borrowed money to pay for prescriptions. Older patients reported less financial burden compared to younger patients (p<0.001). Patients with greater financial burden reported lower levels of satisfaction with their cancer care (p=0.001). Conclusions: OOPE incurred by underinsured cancer patients triggered considerable lifestyle changes. OOPE might impact cancer care quality as patients took fewer prescribed medications. Patients saddled with OOPE were less satisfied with cancer care. OOPE thus diminished care at multiple levels.
Parathyroid reimplantation with PR-FaST technique in unselected patients during thyroidectomy. A case series with long term follow up confirming graft vitality and parathormone production
Authors: Giuseppe Cavallaro, Olga Iorio, Marco Centanni, Lucilla Gargano, Susanna Del Duca, Angela Gurrado, Natale Porta, Vincenzo Petrozza, Mario Testini, Giorgio De Toma
Journal: International Journal of Surgery (2017)
Leukocytosis as an Independent Risk Factor for Thrombosis in Polycythemia Vera.
Authors: Raffaele Landolfi, Leonardo Di Gennaro, Tiziano Barbui, Valerio De Stefano, Rosamaria Marfisi, Gianni Tognoni, Francesco Equitani, Guido Finazzi, Roberto Marchioli
Journal: Blood (2006)
Negative Depletion of B Cells and T Cells Expressing the αβ Chain of the T-Cell Receptor (TCR) for Haploidentical Stem Cell Transplantation
Authors: Giuseppina Li Pira, Fabiola Landi, Perla Filippini, Paola Giustiniani, Alice Bertaina, Daria Pagliara, Rita M Pinto, Katia Girardi, Giovanna Del Principe, Stefano Ceccarelli, Franco Locatelli, Sergio Rutella
Journal: Blood (2012)